Skip to Content

62 Results Found

  • Review
  • Open Access
2 Citations
3,448 Views
15 Pages

20 November 2023

This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) improve clinical outcomes in patients with myeloma; however, refractoriness to...

(This article belongs to the Section Medical Research)
  • Review
  • Open Access
27 Citations
7,410 Views
20 Pages

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

  • Felipe de Arriba de la Fuente,
  • Carmen Montes Gaisán and
  • Javier de la Rubia Comos

27 December 2022

Although lenalidomide-based combinations, such as lenalidomide plus a proteasome inhibitor or an anti-CD38 monoclonal antibody, improve the overall response rate, progression-free survival, and overall survival of patients with relapsed/refractory mu...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
10 Citations
5,434 Views
20 Pages

Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma

  • Katia Mancuso,
  • Simona Barbato,
  • Francesco Di Raimondo,
  • Francesca Gay and ,
  • Pellegrino Musto,
  • Massimo Offidani,
  • Maria Teresa Petrucci,
  • Elena Zamagni,
  • Renato Zambello and
  • Michele Cavo
  • + 5 authors+ 0 author

30 March 2025

The therapeutic landscape for multiple myeloma has gradually expanded in recent decades, leading to unprecedented deep and sustained responses as well as remarkable improvements in patient survival. Nonetheless, changes in treatment algorithms have r...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
5 Citations
3,100 Views
11 Pages

19 October 2024

Background/Objectives: Patients with multiple myeloma (MM) who relapse after exposure to lenalidomide in the context of their first-line therapy are becoming a growing and clinically relevant population. We performed a systematic review of available...

(This article belongs to the Section Hematology)
  • Case Report
  • Open Access
8 Citations
1,022 Views
3 Pages

2 November 2016

Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematologic malignancy that often results in transfusion dependency and a hypercoagulable state. This rare disease currently lacks formal guidelines for trea...

  • Article
  • Open Access
1,667 Views
14 Pages

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis

  • Sabrina Pelliccia,
  • Marta Banchi,
  • Lucrezia De Marchi,
  • Emanuele Cencini and ,
  • Claudia Seimonte,
  • Alberto Fabbri,
  • Andrea Nunzi,
  • Susanna Destefano,
  • Guido Bocci and
  • Maria Christina Cox
  • + 5 authors+ 0 author

22 January 2026

Background/Objectives: Relapsed or refractory follicular lymphoma (rrFL) remains difficult to treat in elderly or frail patients who cannot tolerate standard-dose immuno-chemotherapy as well as novel therapies. Metronomic chemotherapy (mCHEMO) may of...

(This article belongs to the Section Clinical Research in Cancer)
  • Article
  • Open Access
1 Citations
1,557 Views
14 Pages

Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)

  • Yvonne Efebera,
  • Vera Suman,
  • Shira Dinner,
  • Taylor O’Donnell and ,
  • Ashley Rosko,
  • John Mckay,
  • Peter Barth,
  • Patrick Hagen,
  • Saad Usmani and
  • Jacob Laubach
  • + 6 authors+ 1 author

23 July 2025

Background: Studies have suggested a synergism between lenalidomide (LEN) and ibrutinib (IBR) in multiple myeloma (MM). Both downregulate IRF4, a key target and master transcriptional factor regulating myeloma cell survival. Method: A 3 + 3 phase I t...

(This article belongs to the Special Issue Multiple Myeloma: Diagnosis and Therapy)
  • Article
  • Open Access
1 Citations
1,300 Views
13 Pages

Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis

  • Hermina Sánta,
  • Laura Regáli,
  • László Váróczy,
  • Virág Szita and ,
  • Ádám Wiedemann,
  • Lóránt Varju,
  • László Rejtő,
  • Norbert Sándor Bartha,
  • Dorottya Máté and
  • Gábor Mikala
  • + 15 authors+ 10 authors

30 December 2025

Background/Objectives: Despite therapeutic advances, managing relapsed/refractory multiple myeloma (RRMM) remains challenging. For patients with frailty, comorbidities, mobility limitations, or when treatment preference and drug accessibility are key...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
10 Citations
5,384 Views
13 Pages

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy

  • Jiri Minarik,
  • Jakub Radocha,
  • Alexandra Jungova,
  • Jan Straub and ,
  • Tomas Jelinek,
  • Tomas Pika,
  • Ludek Pour,
  • Petr Pavlicek,
  • Lubica Harvanova and
  • Roman Hajek
  • + 14 authors+ 9 authors

21 October 2022

Background: We confirmed the benefit of addition of ixazomib to lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM) in unselected real-world population. We report the final analysis for overall survival (OS...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
2 Citations
1,182 Views
14 Pages

Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study

  • Pier Luigi Zinzani,
  • Nicola Battaglia,
  • Mario Lapecorella,
  • Guido Gini and ,
  • Maria Cristina Cox,
  • Stefan Hohaus and
  • Antonio Pinto
  • + 2 authors+ 0 author

15 December 2025

Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) exhibits substantial clinical heterogeneity and poor prognosis in relapsed/refractory (R/R) settings. PRO-MIND is a prospective, multicenter real-world study evaluating tafasitamab–le...

  • Article
  • Open Access
26 Citations
5,081 Views
16 Pages

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

  • Concetta Conticello,
  • Alessandra Romano,
  • Vittorio Del Fabro,
  • Enrica Antonia Martino and ,
  • Valeria Calafiore,
  • Giuseppe Sapienza,
  • Valerio Leotta,
  • Marina Silvia Parisi,
  • Uros Markovic and
  • Francesco Di Raimondo
  • + 23 authors+ 18 authors

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
17 Citations
4,030 Views
13 Pages

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

  • Marc-Andrea Baertsch,
  • Mathilde Fougereau,
  • Thomas Hielscher,
  • Sandra Sauer and ,
  • Iris Breitkreutz,
  • Karin Jordan,
  • Carsten Müller-Tidow,
  • Hartmut Goldschmidt,
  • Marc-Steffen Raab and
  • Nicola Giesen
  • + 6 authors+ 1 author

20 September 2021

Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-o...

(This article belongs to the Special Issue Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy)
  • Article
  • Open Access
5 Citations
4,387 Views
12 Pages

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study

  • Damian Mikulski,
  • Paweł Robak,
  • Wiktoria Ryżewska,
  • Kamila Stańczak and ,
  • Kacper Kościelny,
  • Joanna Góra-Tybor and
  • Tadeusz Robak
  • + 2 authors+ 0 author

7 October 2022

Lenalidomide-based regimens are effective treatment options for patients with relapsed/refractory multiple myeloma (RRMM). However, they are associated with an increased risk of infectious complications. This study examines the clinical factors influ...

(This article belongs to the Special Issue Infectious Complications after Chemotherapy and Hematopoietic Stem Cell Transplantation)
  • Article
  • Open Access
3 Citations
2,207 Views
10 Pages

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)

  • Josip Batinić,
  • Barbara Dreta,
  • Goran Rinčić,
  • Antonia Mrdeža and ,
  • Karla Mišura Jakobac,
  • Delfa Radić Krišto,
  • Milan Vujčić,
  • Mario Piršić,
  • Željko Jonjić and
  • Sandra Bašić-Kinda
  • + 14 authors+ 9 authors

20 November 2024

Background and Objectives: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). Materials and Methods: This study evaluates the real-world effe...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
2 Citations
2,236 Views
17 Pages

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

  • Ioannis Petrakis,
  • Christos Kontogiorgis,
  • Evangelia Nena,
  • Sosana Delimpasi and ,
  • Natasa E. Loutsidi,
  • Emmanouil Spanoudakis,
  • Stergios Intzes,
  • Christina Misidou,
  • Marianthi Symeonidou and
  • Evangelos Terpos
  • + 7 authors+ 2 authors

14 December 2023

Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical be...

(This article belongs to the Section Cancer Drug Development)
  • Article
  • Open Access
5 Citations
4,985 Views
16 Pages

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

  • Evangelos Terpos,
  • Panagiotis Repousis,
  • Chrysavgi Lalayanni,
  • Evdoxia Hatjiharissi and ,
  • Theodora Assimakopoulou,
  • Georgios Vassilopoulos,
  • Anastasia Pouli,
  • Emmanouil Spanoudakis,
  • Eurydiki Michalis and
  • Eirini Katodritou
  • + 17 authors+ 12 authors

5 April 2021

The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible ad...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
12 Citations
3,858 Views
14 Pages

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe

  • Evangelos Terpos,
  • Renato Zambello,
  • Xavier Leleu,
  • Thomas Kuehr and ,
  • Sorina N. Badelita,
  • Eirini Katodritou,
  • Alessandra Brescianini,
  • Tony Liang,
  • Sally Wetten and
  • Jo Caers
  • + 5 authors+ 0 author

28 October 2022

This prospective, observational study examined the real-world use of carfilzomib across 11 European countries in adults with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy. Carfilzomib and dexamethasone (K...

(This article belongs to the Section Cancer Therapy)
  • Correction
  • Open Access
840 Views
4 Pages

Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168

  • Katia Mancuso,
  • Simona Barbato,
  • Francesco Di Raimondo,
  • Francesca Gay and ,
  • Pellegrino Musto,
  • Massimo Offidani,
  • Maria Teresa Petrucci,
  • Elena Zamagni,
  • Renato Zambello and
  • Michele Cavo
  • + 5 authors+ 0 author

1 August 2025

The authors have separated the affiliations originally listed in affiliation 4—this is so both affiliations can be organized from subordinate to superior [...]

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
7 Citations
4,146 Views
17 Pages

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma

  • Sikander Ailawadhi,
  • Ricardo D. Parrondo,
  • Navnita Dutta,
  • Bing Han and ,
  • Gina Ciccio,
  • Yesesri Cherukuri,
  • Victoria R. Alegria,
  • Betsy R. LaPlant,
  • Vivek Roy and
  • Aneel Paulus
  • + 16 authors+ 11 authors

12 January 2023

Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces...

(This article belongs to the Special Issue Emerging Treatment Strategies for Multiple Myeloma)
  • Case Report
  • Open Access
9 Citations
4,478 Views
12 Pages

18 July 2022

Plasmablastic lymphoma is a rare subtype of large B-cell lymphoma characterised by an aggressive clinical course with frequent relapses and refractoriness to chemotherapy. It is usually associated with HIV, however, it can also be seen in immunocompe...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
6 Citations
3,397 Views
12 Pages

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group

  • Norbert Grzasko,
  • Grzegorz Charlinski,
  • Marta Morawska,
  • Pawel Kicinski and ,
  • Anna Waszczuk-Gajda,
  • Joanna Drozd-Sokolowska,
  • Edyta Subocz,
  • Danuta Blonska,
  • Malgorzata Razny and
  • Krzysztof Giannopoulos
  • + 10 authors+ 5 authors

24 November 2021

Multiple myeloma (MM) is an incurable disease and patients become refractory to the treatment in the course of the disease. Bendamustine-based regimens containing steroids and other agents are among the therapeutic options offered to MM patients. Her...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
7 Citations
1,150 Views
5 Pages

1 April 2007

Oral melphalan and prednisone remain an effective and tolerable treatment for patients with multiple myeloma. For approximately 40 years, this combination has been the standard of care for patients not proceeding to stem cell transplant. Within the l...

  • Article
  • Open Access
4 Citations
3,793 Views
12 Pages

Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study

  • Nicola Sgherza,
  • Olga Battisti,
  • Paola Curci,
  • Concetta Conticello and ,
  • Salvatore Palmieri,
  • Daniele Derudas,
  • Candida Germano,
  • Enrica Antonia Martino,
  • Giuseppe Mele and
  • Pellegrino Musto
  • + 19 authors+ 14 authors

19 April 2025

Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory mu...

(This article belongs to the Special Issue Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma 2024)
  • Article
  • Open Access
16 Citations
1,602 Views
14 Pages

Lenalidomide in Multiple Myeloma—A Practice Guideline

  • C. Chen,
  • F. Baldassarre,
  • S. Kanjeekal,
  • J. Herst and ,
  • L. Hicks and
  • M. Cheung
  • + 1 author+ 0 author

1 April 2013

Background: Promising new drugs such as lenalidomide, an immunomodulatory agent, are available for the treatment of multiple myeloma. We describe the process of creating a provincial guideline for the use of lenalidomide, alone or in combination with...

  • Review
  • Open Access
31 Citations
6,563 Views
18 Pages

17 September 2021

Over the past two decades, the improvement in our understanding of the biology of MM and the introduction of new drug classes, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PI), and monoclonal antibodies (MoAb), have significantly...

(This article belongs to the Special Issue Multiple Myeloma: Targeted Therapy and Immunotherapy)
  • Article
  • Open Access
13 Citations
3,573 Views
14 Pages

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial

  • Carlos Jiménez-Cortegana,
  • Pilar M. Sánchez-Martínez,
  • Natalia Palazón-Carrión,
  • Esteban Nogales-Fernández and ,
  • Fernando Henao-Carrasco,
  • Alejandro Martín García-Sancho,
  • Antonio Rueda,
  • Mariano Provencio,
  • Luis de la Cruz-Merino and
  • Víctor Sánchez-Margalet
  • + 5 authors+ 0 author

15 September 2021

The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial (Eudr...

(This article belongs to the Special Issue Tumor Immune Microenvironment in Lymphoproliferative Syndromes)
  • Review
  • Open Access
29 Citations
10,467 Views
15 Pages

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options

  • Alejandro Martín García-Sancho,
  • Almudena Cabero and
  • Norma C. Gutiérrez

22 December 2023

Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory disease or relapse after the first line of treatment. Until relatively recently, the prognosis of patients with relapsed or refractory DLBCL was very poor and...

(This article belongs to the Section Hematology)
  • Review
  • Open Access
9 Citations
8,605 Views
19 Pages

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma

  • Omar Nadeem,
  • Sikander Ailawadhi,
  • Jack Khouri,
  • Louis Williams and ,
  • Donna Catamero,
  • Kathryn Maples and
  • Jesús Berdeja
  • + 2 authors+ 0 author

29 February 2024

Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved surv...

(This article belongs to the Section Clinical Research in Cancer)
  • Review
  • Open Access
38 Citations
8,175 Views
22 Pages

Immunomodulatory Drugs for the Treatment of B Cell Malignancies

  • Nikolaos Ioannou,
  • Khushi Jain and
  • Alan G. Ramsay

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in disease progression and drug resistance in B cell malignancies, by supporting tumor growth and facilitating the ability of malignant cells to avoid immune recognition...

(This article belongs to the Special Issue Tumor Microenvironment from a Precision Medicine Perspective)
  • Review
  • Open Access
34 Citations
11,104 Views
17 Pages

10 December 2021

Approximately 40% of patients with diffuse large B cell lymphoma (DLBCL) do not respond or develop relapsed disease after first-line chemoimmunotherapy. A minority of these patients can be cured with autologous hematopoietic stem cell transplantation...

(This article belongs to the Special Issue Emerging Therapies and Personalized Medicine in Lymphomas)
  • Review
  • Open Access
3 Citations
5,730 Views
15 Pages

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

  • Christie P. M. Verkleij,
  • Wassilis S. C. Bruins,
  • Sonja Zweegman and
  • Niels W. C. J. van de Donk

1 March 2021

In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care...

(This article belongs to the Special Issue Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton)
  • Article
  • Open Access
5 Citations
3,706 Views
13 Pages

Carfilzomib’s Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records

  • Ha Young Jang,
  • Hyun Kyung Lee,
  • Chae Jeong Kim,
  • Sung-Soo Yoon and ,
  • In-Wha Kim and
  • Jung Mi Oh
  • + 1 author+ 0 author

Carfilzomib is a promising anticancer drug for relapsed/refractory multiple myeloma (RRMM). However, real-world evidence has only investigated the cardiovascular safety of carfilzomib, and there is a high demand for thorough safety evaluations. We ai...

(This article belongs to the Special Issue Cancer Care: Challenges and Opportunities)
  • Article
  • Open Access
3 Citations
3,497 Views
20 Pages

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma

  • Alpay Yeşilaltay,
  • Dilek Muz,
  • Berna Erdal,
  • Türker Bilgen and ,
  • Bahadır Batar,
  • Burhan Turgut,
  • Birol Topçu,
  • Bahar Yılmaz and
  • Burcu Altındağ Avcı
  • + 4 authors+ 0 author

12 January 2024

This study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, an...

(This article belongs to the Section Vaccines and Therapeutic Developments)
  • Review
  • Open Access
33 Citations
7,750 Views
17 Pages

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020

  • Arthur Bobin,
  • Evelyne Liuu,
  • Niels Moya,
  • Cécile Gruchet and ,
  • Florence Sabirou,
  • Anthony Lévy,
  • Hélène Gardeney,
  • Laly Nsiala,
  • Laura Cailly and
  • Mathieu Puyade
  • + 11 authors+ 6 authors

8 October 2020

The survival rate of multiple myeloma (MM) patients has drastically increased recently as a result of the wide treatment options now available. Younger patients truly benefit from these innovations as they can support more intensive treatment, such a...

(This article belongs to the Special Issue Recent Advances on the Pathobiology and Treatment of Multiple Myeloma)
  • Interesting Images
  • Open Access
1 Citations
7,000 Views
5 Pages

Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disea...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Review
  • Open Access
18 Citations
5,007 Views
14 Pages

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment

  • Antonio Piccolomo,
  • Claudia Pia Schifone,
  • Vanda Strafella,
  • Giorgina Specchia and ,
  • Pellegrino Musto and
  • Francesco Albano
  • + 1 author+ 0 author

5 September 2020

Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties and exert a role in regulating the tumor microenvironment. Recently IMiDs have been investigated for their pleiotropic p...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
7 Citations
4,054 Views
14 Pages

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

  • Valeria Calafiore,
  • Silvia Giamporcaro,
  • Concetta Conticello,
  • Alessandra Romano and ,
  • Marina Parisi,
  • Gaetano Giuffrida,
  • Daniele Tibullo,
  • Francesco Di Raimondo and
  • Salvatore Santo Signorelli
  • + 4 authors+ 0 author

5 September 2020

Compared to the general population, patients with multiple myeloma (MM) have a nine-fold increased risk of developing venous thromboembolism (VTE). Little is known about VTE prophylaxis in relapsed/refractory (RR) MM patients treated with next genera...

(This article belongs to the Section Hematology)
  • Review
  • Open Access
1 Citations
2,210 Views
12 Pages

Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review

  • Marwa Nassar,
  • Nourah Alzaidy,
  • Abdulrahman Nasiri,
  • Amr Hanbali and ,
  • Mahmoud A. Aljurf and
  • Mostafa F. Mohammed Saleh
  • + 1 author+ 0 author

28 February 2026

Background: The role of second or salvage autologous stem cell transplantation (ASCT2) in relapsed multiple myeloma (MM) has evolved substantially over the past decade with the introduction of novel agents, maintenance strategies, and cellular immuno...

(This article belongs to the Section Hematology)
  • Review
  • Open Access
39 Citations
6,703 Views
9 Pages

The Anti-CD38 Antibody Therapy in Multiple Myeloma

  • Maria Teresa Petrucci and
  • Federico Vozella

12 December 2019

Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the m...

(This article belongs to the Special Issue CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology)
  • Review
  • Open Access
22 Citations
9,202 Views
17 Pages

Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

  • Monique A. Hartley-Brown,
  • Clifton C. Mo,
  • Omar Nadeem,
  • Shonali Midha and ,
  • Jacob P. Laubach and
  • Paul G. Richardson
  • + 1 author+ 0 author

15 March 2024

Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM). Like other CELMoD compounds, mezigdomide acts by altering the conformation of cereblon w...

(This article belongs to the Section Cancer Therapy)
  • Feature Paper
  • Review
  • Open Access
7 Citations
8,483 Views
25 Pages

Current Treatment Strategies for Multiple Myeloma at First Relapse

  • Evangelos Mavrothalassitis,
  • Konstantinos Triantafyllakis,
  • Panagiotis Malandrakis,
  • Maria Gavriatopoulou and ,
  • Martina Kleber and
  • Ioannis Ntanasis-Stathopoulos
  • + 1 author+ 0 author

28 February 2025

Multiple myeloma (MM), the second most common hematologic cancer, remains an incurable malignancy, characterized by an initial response to therapy followed by successive relapses. The upfront treatment typically involves induction therapy, autologous...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
2,148 Views
15 Pages

Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics

  • Annita-Ioanna Gkioka,
  • Alexandros Gkiokas,
  • Mavra Papadatou-Gigante,
  • Alexandros Alexandropoulos and ,
  • Thomai-Marina Tryfou,
  • Aspasia Koudouna,
  • Vasiliki Bartzi and
  • Marie-Christine Kyrtsonis
  • + 3 authors+ 0 author

Serum cereblon (CRBN) has been proposed as a target protein for immunomodulatory drugs (IMiDs). IMiDs are one of the backbone treatment options in multiple myeloma (MM), rendering CRBN an intriguing candidate for use as a biomarker in clinical settin...

(This article belongs to the Special Issue Immunomodulatory Molecules in Cancer)
  • Review
  • Open Access
9 Citations
7,679 Views
21 Pages

4 September 2025

Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma confined to the central nervous system. The cancer biology of PCNSL remains incomplete and is often associated with genetic aberrations with abnormal signaling...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
3 Citations
3,622 Views
12 Pages

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils

  • Alessandra Romano,
  • Nunziatina Laura Parrinello,
  • Marina Parisi,
  • Vittorio Del Fabro and ,
  • Angelo Curtopelle,
  • Salvatore Leotta,
  • Concetta Conticello and
  • Francesco Di Raimondo
  • + 3 authors+ 0 author

Background Myeloid dysfunction is an emerging hallmark of microenvironment changes occurring in multiple myeloma (MM). Our previous work showed that FcγRI/CD64 overexpression in neutrophils of newly diagnosed MM patients is associated to inferior out...

(This article belongs to the Special Issue Neutrophils, Fast and Strong)
  • Systematic Review
  • Open Access
4 Citations
3,515 Views
13 Pages

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review

  • Tung-Lung Yang,
  • Chin Lin,
  • Ching-Liang Ho,
  • Tzu-Chuan Huang and ,
  • Yi-Ying Wu,
  • Hong-Jie Jhou,
  • Po-Huang Chen and
  • Cho-Hao Lee
  • + 3 authors+ 0 author

27 November 2023

Background: Over the last decade, many studies have assessed the efficacy of treatments for refractory/relapsed multiple myeloma (R/R MM). While combination therapies show greater efficacy than traditional methods, limited research has targeted elder...

(This article belongs to the Section Medical Research)
  • Feature Paper
  • Review
  • Open Access
9 Citations
4,494 Views
20 Pages

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

  • Sonia Morè,
  • Maria Teresa Petrucci,
  • Laura Corvatta,
  • Francesca Fazio and ,
  • Massimo Offidani and
  • Attilio Olivieri
  • + 1 author+ 0 author

27 November 2020

Multiple myeloma is a complex hematologic malignancy, and despite a survival improvement related to the growing number of available therapeutic options since 2000s, it remains an incurable disease with most patients experiencing relapse. However, the...

(This article belongs to the Special Issue Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma)
  • Review
  • Open Access
35 Citations
8,868 Views
12 Pages

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Leonard Jeff Harris,
  • Kruti Patel and
  • Michael Martin

13 November 2020

The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies...

(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
  • Review
  • Open Access
14 Citations
5,155 Views
24 Pages

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

  • Georg Jeryczynski,
  • Arnold Bolomsky,
  • Hermine Agis and
  • Maria-Theresa Krauth

23 November 2021

The treatment landscape for relapsed multiple myeloma (RRMM) has experienced an unprecedented wave of innovation. Implementation of numerous new substances and drug classes with different modes of action is made possible in routine clinical practice....

(This article belongs to the Special Issue Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond)
  • Review
  • Open Access
44 Citations
15,489 Views
15 Pages

Primary Effusion Lymphoma: A Clinicopathologic Perspective

  • Diamone A. Gathers,
  • Emily Galloway,
  • Katalin Kelemen,
  • Allison Rosenthal and ,
  • Sarah E. Gibson and
  • Javier Munoz
  • + 1 author+ 0 author

30 January 2022

Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the ar...

(This article belongs to the Section Tumor Microenvironment)
  • Article
  • Open Access
611 Views
16 Pages

A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects

  • Marcelo Gomes Davanço,
  • Thaís Pereira Vespasiano,
  • Jessé Moisan,
  • Oscar Gonzalez and ,
  • Milesa Sarmiento and
  • Mélanie Groleau
  • + 1 author+ 0 author

15 July 2026

Background: Multiple myeloma (MM) is a mature B-cell disorder characterized by the excessive production of monoclonal immunoglobulins. It is the second most common hematological cancer and predominantly affects older adults. In 2022, there were appro...

(This article belongs to the Special Issue Pharmacokinetics and Pharmacometrics Driving Innovation)

of 2